NFL Biosciences
Pre-clinicalNFL-101 & NFL-102: An innovative drug candidate for smoking cessation derived from a nicotine-free tobacco leaf protein extract
Founded
2015
Focus
Small Molecules
About
NFL-101 & NFL-102: An innovative drug candidate for smoking cessation derived from a nicotine-free tobacco leaf protein extract
Funding History
1Total raised: $8.2M
IPO$8.2MEuronext ParisDec 15, 2021
Company Info
TypePrivate
Founded2015
LocationMontpellier, France
StagePre-clinical
Contact
Sectors
SIMILAR COMPANIES
4P-Pharma
Phase 2 · Lille
Patheon
Pre-clinical · Lyon
ABL Diagnostics
Pre-clinical · Strasbourg
Acticor Biotech
Pre-clinical · Paris
Adjuvatis
Pre-clinical · Lyon
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile